Skip to Content

IR Biosciences Holdings Inc IRBS

Morningstar Rating
$0.00 0.00 (0.00%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

IRBS is trading at a 60% discount.
Price
$0.00
Fair Value
$7.30
Uncertainty
Extreme
1-Star Price
$2.44
5-Star Price
Economic Moat
Hmgz
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if IRBS is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.00
Day Range
$0.000.00
52-Week Range
$0.000.00
Bid/Ask
/
Market Cap
$17.08
Volume/Avg
110,083 / 110,083

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

IR Biosciences Holdings Inc is a development-stage biotechnology company engaged in the research & development of potential drug candidate, Homspera and its derivatives, Radilex and Viprovex through its subsidiary, ImmuneRegen BioSciences, Inc. It is engaged in the research and development of therapies in the areas of pulmonary fibrosis, influenza infection, and radiation-induced Neutropenia.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Total Number of Employees
4

Valuation

Metric
IRBS
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
IRBS
Quick Ratio
Current Ratio
0.01
Interest Coverage
−2.10
Quick Ratio
No chart available

Profitability

Metric
IRBS
Return on Assets (Normalized)
−3,921.13%
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
Return on Assets
No chart available
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRYms$550.2 Bil
VRTX
Vertex Pharmaceuticals IncCcpxtkf$111.1 Bil
REGN
Regeneron Pharmaceuticals IncWqxzfv$107.6 Bil
MRNA
Moderna IncZzbp$36.8 Bil
ARGX
argenx SE ADRPkm$24.2 Bil
BNTX
BioNTech SE ADRCkhr$22.4 Bil
ALNY
Alnylam Pharmaceuticals IncNbfhxr$19.9 Bil
BMRN
Biomarin Pharmaceutical IncKksgjsr$17.2 Bil
RPRX
Royalty Pharma PLC Class AClxxht$13.9 Bil
INCY
Incyte CorpHmjlgg$13.6 Bil

Sponsor Center